Compare Lemonade Inc (LMND) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Lemonade (LMND) trades at $67.47, up 0.43% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Revenue growth is accelerating, reaching $738 million in 2025, while net losses are narrowing to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, supporting optimism for future profitability.

The outlook is mixed: strong top-line growth and path to EBITDA positivity offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus targets $69.60, with 33% buy ratings, reflecting cautious optimism amid execution challenges in the competitive insurance sector.

DENTSPLY SIRONA (XRAY) trades at $13.57, down 3.48% with bearish technical indicators despite a bullish moving average signal. The company shows persistent challenges with negative net income margins (-17.06%) and declining revenue trends from $3.9B in 2022 to $3.7B in 2025. Recent Q1 2026 earnings missed estimates ($0.27 vs. $0.28 expected), continuing a pattern of underperformance. Analyst sentiment remains cautious with a 'Hold' consensus rating and $13.33 price target, slightly below current levels.

The stock faces significant fundamental headwinds including consecutive earnings misses, declining profitability, and rising debt-to-asset ratio (42.88% in 2025). While technical indicators show some bullish momentum, the weak financial performance and negative investor sentiment suggest limited near-term upside potential. The appointment of a new CFO and distribution expansions provide some operational optimism, but execution risks remain elevated.